Fractyl Health Inc GUTS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
GUTS CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Fractyl (NASDAQ: GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law Firm
Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
SueWallSt Reminds Fractyl Health, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 20, 2026 - GUTS
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers - GUTS
Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GUTS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Fractyl Health, Inc. Securities Lawsuit - Contact Levi & Korsinsky
Robbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class Action
Trading Information
- Previous Close Price
- $0.90
- Day Range
- $0.93–0.93
- 52-Week Range
- $0.84–29.28
- Bid/Ask
- $0.92 / $0.94
- Shares Outstanding
- 13.26M
- Market Cap
- $12.12M
- Volume/Avg
- 3,660 / 465,389
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 73
- Website
- https://www.fractyl.com
Valuation
Metric | GUTS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | GUTS |
|---|---|
Quick Ratio | 3.00 |
Current Ratio | 3.15 |
Interest Coverage | — |
Quick Ratio
GUTS
Profitability
Metric | GUTS |
|---|---|
Return on Assets (Normalized) | −83.84% |
Return on Equity (Normalized) | −5,162.15% |
Return on Invested Capital (Normalized) | −130.46% |
Return on Assets
GUTS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|#?@#LB | LOCK|bn<h$ | $138B | |||
| Moderna Inc MRNA | LOCK|b>Xwvl | LOCK|LPp | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|yzBVlM& | LOCK|jZJ# | $93B | |||
| argenx SE ADR ARGX | LOCK|<!$D!SV | LOCK|@Jr | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|PQpLWg! | LOCK|#M | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|qNlz@q>m | LOCK|s%W>J | $30B | |||
| Incyte Corp INCY | LOCK|>!Yr@Rm | LOCK|#XV | $24B | |||
| BioNTech SE ADR BNTX | LOCK|h<N%%QQ | LOCK|FZ | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%&<GB#$ | LOCK|@W%# | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|@ySZ?ys | LOCK|#b | $15B |
United States